Churchill Financial Advisors LLC Invests $593,000 in Stryker Corporation $SYK

Churchill Financial Advisors LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 1,686 shares of the medical technology company’s stock, valued at approximately $593,000.

Several other large investors also recently modified their holdings of the stock. United Financial Planning Group LLC acquired a new stake in Stryker in the third quarter valued at about $27,000. Strive Asset Management LLC acquired a new stake in Stryker in the third quarter valued at about $30,000. CGC Financial Services LLC acquired a new stake in Stryker in the fourth quarter valued at about $29,000. ANTIPODES PARTNERS Ltd acquired a new stake in Stryker in the third quarter valued at about $34,000. Finally, Copia Wealth Management boosted its stake in Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after buying an additional 69 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.60% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $316.39 on Monday. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $121.29 billion, a PE ratio of 36.62, a P/E/G ratio of 1.99 and a beta of 0.80. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The stock has a 50-day moving average price of $325.22 and a two-hundred day moving average price of $349.76.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Wells Fargo & Company reduced their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Weiss Ratings lowered Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Evercore set a $355.00 price objective on Stryker in a research note on Friday, May 1st. Truist Financial reaffirmed a “hold” rating and issued a $330.00 price objective (down from $380.00) on shares of Stryker in a research note on Monday, May 4th. Finally, Sanford C. Bernstein set a $410.00 price objective on Stryker in a research note on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.